NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04102098,A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation,https://clinicaltrials.gov/study/NCT04102098,IMbrave050,ACTIVE_NOT_RECRUITING,This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.,YES,"Carcinoma, Hepatocellular",DRUG: Atezolizumab|DRUG: Bevacizumab,"Recurrence-Free Survival (RFS), as Determined by IRF, RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first)., Baseline up to approximately 33 months","Overall Survival (OS), OS is defined as the time from randomization to death from any cause., Baseline up to approximately 91 months|RFS as Determined by the Investigator, RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an investigator, or death from any cause (whichever occurs first)., Baseline up to approximately 91 months|Time to Recurrence (TTR), TTR defined as the time from randomization to first documented occurrence of intrahepatic or extrahepatic HCC, as determined by the investigator and by an IRF., Baseline up to approximately 91 months|RFS Rate at 24 and 36 Months, as Assessed by the IRF, Randomization up to 24 months and up to 36 months|RFS Rate at 24 and 36 Months, as Assessed by the Investigator, Randomization up to 24 months and up to 36 months|OS Rate at 24 and 36 Months, OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization., Baseline to 24 and 36 months|Time to Extrahepatic Spread (EHS) or Macrovascular Invasion, Time to EHS or macrovascular invasion after randomization, defined as the time from randomization to the first appearance of EHS or macrovascular invasion, as determined by the investigator., Baseline up to approximately 91 months|RFS in Pd-L1-High Subgroup, RFS after randomization as determined by the investigator and by an IRF, among patients in the PD-L1-high subgroup., Baseline up to approximately 91 months|Percentage of Participants With Adverse Events, Baseline up to approximately 91 months|Serum Concentration of Atezolizumab, Serum concentration of atezolizumab., Prior to any drug administration on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16, and 30 minutes after end of atezolizumab infusion on Day 1 of Cycle 1 (each cycle is 21 days)|Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab, Number of participants with anti-drug antibodies to atezolizumab., Prior to any drug administration up to approximately 33 month",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,668,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WO41535|2019-002491-14,2019-12-31,2022-10-21,2027-07-16,2019-09-25,2023-11-18,2025-03-25,"Kaiser Permanente Los Angeles, Los Angeles, California, 90027, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Columbia University Medical Center, New York, New York, 10032, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States|The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Swedish Cancer Inst., Seattle, Washington, 98104, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Lkh-Univ. Klinikum Graz, Graz, 8036, Austria|Klinikum Klagenfurt am Wörtersee, Klagenfurt, 9020, Austria|Medizinische Universität Wien, Wien, 1090, Austria|Imeldaziekenhuis, Bonheiden, 2820, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|Hospital Sao Rafael - HSR, Salvador, Bahia, 41253-190, Brazil|Sociedade beneficente de senhoras Hospital Sirio Libanes, Brasilia, Distrito Federal, 70200-730, Brazil|Hospital do Cancer UOPECCAN, Cascavel, Paraná, 85806-300, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, São Paulo, 01323-020, Brazil|Gordon & Leslie Diamond Health Care Centre, Vancouver, British Columbia, V5Z 1M9, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, H4A 3J1, Canada|Anhui Provincial Hospital, Anhui, 230001, China|Beijing Cancer Hospital, Beijing, 100142, China|Peking Union Medical College Hospital, Beijing, 100730, China|Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China|The First Hospital of Jilin University, Changchun City, 130021, China|West China Hospital, Sichuan University, Chengdu, 610041, China|Daping Hospital of Third Military Medical University, Chongqing, 400042, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, 116027, China|Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou City, 350025, China|Fujian Cancer Hospital, Fuzhou, 350014, China|Cancer Center of Guangzhou Medical University, Guangzhou, 510000, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China|Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China|Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China|Zhejiang Cancer Hospital, Hangzhou City, 310022, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Anhui Province Cancer Hospital, Hefei, 12345, China|The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China|Shandong Cancer Hospital, Jinan, 250117, China|The 81st Hospital of P.L.A., Nanjing City, 210002, China|Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210029, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, 530021, China|The First Affiliate Hospital of Guangxi Medical University, Nanning, 530021, China|Huashan Hospital Affiliated to Fudan University, Shanghai City, 200040, China|Fudan University Shanghai Cancer Center, Shanghai, 200032, China|Zhongshan Hospital Fudan Unvierstiy, Shanghai, 200032, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China|The First Affiliated Hospital of China Medical University, Shenyang City, 110001, China|Shengjing Hospital of China Medical University, ShenYang, 110004, China|Tianjin Cancer Hospital, Tianjin, 300060, China|The Tumor Hospital of Xinjiang Medical University, Urumqi, 830000, China|Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, 430022, China|Renmin Hospital of Wuhan University, Wuhan, 430060, China|Zhongnan Hospital of Wuhan University, Wuhan, 430071, China|Northern Jangsu People's Hospital, Yangzhou, 225001, China|Clinica CIMCA, San José, 10103, Costa Rica|Fakultni nemocnice Brno, Brno, 625 00, Czechia|Fakultni Thomayerova Nemocnice, Praha, 140 59, Czechia|Hopital Jean Minoz, Besancon, 25030, France|Hôpital Avicenne - Groupement Hospitalier Universitaire Paris Seine St Denis, Bobigny Cedex, 93009, France|Hôpital Albert Michallon, La Tronche, 38700, France|Fondation Hopital Saint Joseph, Marseille, 13285, France|CHU Bordeaux - Hôpital Haut-Lévêque, Pessac, 33604, France|Hopital Robert Debre, Reims, 51092, France|Hopital de Pontchaillou, Rennes, 35033, France|CHU de Toulouse - Hôpital Rangueil, Toulouse Cedex 09, 31059, France|Hopitaux de Brabois - Gastro-Entereologie, Vandoeuvre-les-nancy, 54511, France|Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I., Bonn, 53127, Germany|Klinik Johann Wolfgang von Goethe Uni, Frankfurt Am Main, 60590, Germany|Klinikum der Uni Regensburg, Regensburg, 93053, Germany|Universitätsklinikum Ulm, Ulm, 89081, Germany|Queen Mary Hospital, Hong Kong, 0, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Ospedale Regionale Di Parma, Parma, Emilia-Romagna, 43100, Italy|Ospedale Maggiore Policlinico, Milano, Lombardia, 20122, Italy|Asst Santi Paolo E Carlo, Milano, Lombardia, 20142, Italy|Azlenda Ospendaliero-Universitaria Pisana, Pisa, Toscana, 56100, Italy|Chiba University Hospital, Chiba, 260-8677, Japan|Ehime Prefectural Central Hospital, Ehime, 790-0024, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|Sapporo Kosei General Hospital, Hokkaido, 060-0033, Japan|Hyogo Medical University Hospital, Hyogo, 663-8501, Japan|Japanese Red Cross Society Himeji Hospital, Hyogo, 670-8540, Japan|Kanazawa University Hospital, Ishikawa, 920-8641, Japan|Yokohama City University Medical Center, Kanagawa, 232-0024, Japan|Kanagawa Cancer Center, Kanagawa, 241-8515, Japan|Kitasato University Hospital, Kanagawa, 252-0375, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Osaka Red Cross Hospital, Osaka, 543-8555, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Toranomon Hospital, Tokyo, 105-8470, Japan|The University of Tokyo Hospital, Tokyo, 113-8655, Japan|Japanese Red Cross Musashino Hospital, Tokyo, 180-8610, Japan|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Kyungpook National University Hospital, Daegu, 41944, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, 13496, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, 13620, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, 16499, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Boramae Medical Center, Seoul, 07061, Korea, Republic of|Samsung Medical Center, Seoul, 6351, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Filios Alta Medicina, Monterrey, Nuevo LEON, 64460, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Instituto Nacional de Enfermedades Neoplasicas, Lima, 15038, Peru|Clínica San Gabriel, Lima, 15088, Peru|Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Warszawa, 02-781, Poland|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Moskovskaja Oblast, 119991, Russian Federation|Group of companies ""Medci"", Moskva, Moskovskaja Oblast, 105229, Russian Federation|Clinical hospital #1, FBHI Volga district medical center, Federal Medical and Biological Agency, Nizhny Novgorod, Niznij Novgorod, 603109, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Pesochny, Sankt Petersburg, 197758, Russian Federation|National Cancer Centre, Singapore, 168583, Singapore|Tan Tock Seng Hospital, Singapore, 308433, Singapore|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, 28222, Spain|Hospital Universitario Infanta Cristina, Badajoz, 06080, Spain|Hospital General Universitario Gregorio Marañon, Madrid, 28007, Spain|Changhua Christian Hospital, Chang Hua, 500, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, 807, Taiwan|National Taiwan Uni Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 112, Taiwan|Chang Gung Medical Foundation - Linkou, Taoyuan, 333, Taiwan|Rajavithi Hospital, Bangkok, 10400, Thailand|Siriraj Hospital, Bangkok, 10700, Thailand|Chiang Rai Prachanukroh Hospital, Chiang Rai, 57000, Thailand|Chulabhorn Hospital, Lak Si, 10210, Thailand|Adana Baskent University Hospital, Adana, 01120, Turkey","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/98/NCT04102098/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/98/NCT04102098/SAP_001.pdf"
